유럽 ​​전체 엑솜 시퀀싱 시장 – 2029년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

유럽 ​​전체 엑솜 시퀀싱 시장 – 2029년까지의 산업 동향 및 예측

  • Medical Devices
  • Published Report
  • Jun 2022
  • Europe
  • 350 Pages
  • 테이블 수: 152
  • 그림 수: 40

>유럽 ​​전체 엑솜 시퀀싱 시장, 구성요소(2세대 시퀀싱 및 3세대 시퀀싱), 제품 및 서비스(시스템, 키트 및 서비스), 응용 분야(신약 발견 및 개발, 농업 및 동물 연구, 진단, 개인 맞춤 의학 및 기타), 최종 사용자(제약 및 생명 공학 회사, 학계 및 연구 기관, 병원 및 진료소, 임상 실험실 및 기타), 유통 채널(직거래, 소매 판매 및 기타), 산업 동향 및 2029년까지의 예측.

유럽 ​​전체 엑솜 시퀀싱 시장

시장 분석 및 통찰력

유럽 ​​전체 엑솜 시퀀싱 시장은 2022년에서 2029년의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년에서 2029년의 예측 기간 동안 16.0%의 CAGR로 성장하고 있다고 분석합니다. 암과 같은 다양한 만성 질환의 예측, 치료 및 모니터링을 위한 차세대 시퀀싱 방법의 수용 증가는 예측 기간 동안 시장 수요를 촉진한 주요 원동력입니다.

전체 엑솜 시퀀싱 시장그러나 전체 엑솜 시퀀싱 치료와 관련된 기술과 부작용과 관련된 법적 문제는 전체 엑솜 시퀀싱 시장의 미래 성장을 방해할 수 있습니다. 주요 시장 참여자의 파트너십 및 인수와 같은 전략적 제휴 채택은 전체 엑솜 시퀀싱 시장 성장의 기회로 작용합니다.

보고서 메트릭

세부

예측 기간

2022년부터 2029년까지

기준 연도

2021

역사적 연도

2020

양적 단위

수익은 백만 달러, 가격은 미화로 표시됨

다루는 세그먼트

구성 요소별(2세대 시퀀싱 및 3세대 시퀀싱), 제품 및 서비스(시스템, 키트 및 서비스), 응용 프로그램(약물 발견 및 개발, 농업 및 동물 연구, 진단, 개인화 의학 및 기타), 최종 사용자(제약 및 생명 공학 회사, 학술 및 연구 기관, 병원 및 진료소, 임상 실험실 및 기타), 유통 채널(직거래, 소매 판매 및 기타)

적용 국가

독일, 프랑스, ​​이탈리아, 영국, 스페인, 네덜란드, 러시아, 스위스, 터키, 벨기에, 유럽의 나머지 지역

시장 참여자 포함

Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx(Bio-Techne의 일부), FOUNDATION MEDICINE, INC.(F. Hoffmann-La Roche Ltd의 자회사), GeneFirst Limited, CeGaT GmbH, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta US Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics(PerkinElmer Inc.의 자회사), GeneDx, LLC, Psomagen, Integrated DNA Technologies, Inc. 등이 있습니다.

전체 엑솜 시퀀싱 시장 정의

Whole exome is a genomic technique for sequencing all of the protein-coding region of genes in a genome. Whole exome sequencing is available to patients who are searching for a unifying diagnosis for multiple medical conditions. A laboratory process that is used to determine the nucleotide sequence primarily of the exonic (or protein-coding) regions of an individual’s genome and related sequences, representing approximately 1% of the complete DNA sequence, also called WES. Whole-exome sequencing is a widely used whole exome sequencing method that involves sequencing the protein-coding regions of the genome. The human exome represents less than 2% of the genome, but contains ~85% of known disease-related variants, making this method a cost-effective alternative to whole-genome sequencing.

Exome sequencing using exome enrichment can efficiently detect coding variants across a wide range of applications, including population genetics, genetic disease and cancer studies. The growth of the global whole exome sequencing market is attributed to the reduction in time and cost for sequencing. With the development of new technologies and cancer cure treatment, the whole exome sequencing market in clinical oncology has huge potential in the coming years.

Europe Whole exome sequencing Market Dynamics

Drivers

  • Increase in the adoption of next generation sequencing (NGS)

As genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight at molecular underpinnings of individual tumours and specific receptors.

NGS offers advantages in accuracy, sensitivity and speed compared to traditional methods that have the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, the need to order multiple tests to identify the causative mutation is eliminated.

  • Growing usage of targeted sequencing methods

As genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight at molecular underpinnings of individual tumours and specific receptors.

NGS offers advantages in accuracy, sensitivity and speed compared to traditional methods that have the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, the need to order multiple tests to identify the causative mutation is eliminated.

Restraint

  • Less comprehensive coverage of exons

All the exons are not comprehensively captured. The exon of importance may not be included in the current standard annotations of the human genome; and it is merely arduous to cover 100% of the exome with the current WES technology. Consequently, disease-causing variants in these “missed” exons go undetected.

WES has low sensitivity for structural variations, hence detection is limited. Nonetheless some CNVs, including indels and duplications, can be detected by WES, the technical limitation implies that others are likely missed

Opportunity

  • Strategic Initiatives by the key market player

The demand for whole exome sequencing is increasing in the market owing to the increased incidence of genetic disease along with increased geriatric population across the region. Thus, the top market players have implemented the strategy of collaboration with other market players aimed at improving business operations and profitability.

Challenge

  • Ethical and legal issues related to whole exome sequencing

Rapid advances in high throughput genomic technologies and next generation sequencing are making medical genomic research more readily accessible and affordable, including the sequencing of patient and control whole genomes and exomes in order to elucidate genetic factors underlying disease. Progress of high throughput genomic technologies and next generation sequencing (NGS) methods in recent years has changed the scope of human genomic studies. These advances have made it feasible to routinely perform whole exome sequencing (WES) studies.

Due to the large-scale, collaborative nature of studies, ethical and legal issues are of increasing concern and have important implications in Africa. African populations are of unique interest because, despite having the highest levels of genetic diversity, living in a vast array of environmental and cultural settings, as well as suffering from a high burden of disease that could be studied using genomics approaches, they are facing legal issues in WES.

Post COVID-19 Impact on Whole Exome Sequencing Market

COVID-19 has resulted in a substantial upsurge in demand for medical supplies from both healthcare professionals and the general public for precautionary measures. Manufacturers of these items have an opportunity to take advantage of the increased demand for medical supplies by ensuring a steady supply of personal protective equipment on the market. COVID-19 is anticipated to have a big impact on the whole exome sequencing market.

Recent Development

  • In May, 2022, Thermo Fisher Scientific, the world leader in serving science, and Qatar Genome Program (QGP), a member of Qatar Foundation (QF), have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar as a step toward expanding the benefits of precision medicine across Arab populations globally. This has helped the company to expand its presence.
  • 2022년 3월, Illumina, Fulgent Genetics, Invitae, GeneDx, PerkinElmer Genomics를 포함한 몇몇 선도적인 유전체학 기업과 연구소가 CardioGenomic Testing Alliance(CGTA)를 결성했습니다. CGTA는 심장학에서 유전체 검사에 대한 인식과 활용을 높이는 것을 목표로 하는 협력 그룹입니다. CGTA는 의료 제공자와 기타 이해 관계자에게 이러한 검사의 가치에 대해 교육하여 전문 의료 학회의 기존 지침을 준수하고, 의료 관리 및 계단식 검사를 알리고, 임상 결과를 개선하고자 합니다. 이를 통해 회사가 지침을 준수하는 데 도움이 되었습니다.

유럽 ​​전체 엑솜 시퀀싱 시장 세분화

유럽 ​​전체 엑솜 시퀀싱 시장은 구성 요소, 제품 및 서비스, 애플리케이션, 최종 사용자 및 유통 채널을 기준으로 세분화됩니다. 세그먼트 간 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 애플리케이션 영역과 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.

요소

  • 2세대 시퀀싱
  • 3세대 시퀀싱

유럽 ​​전체 엑솜 시퀀싱 시장은 구성 요소를 기준으로 2세대 시퀀싱과 3세대 시퀀싱으로 구분됩니다.

제품 및 서비스

  • 시스템
  • 키트
  • 서비스

유럽 ​​전체 엑솜 시퀀싱 시장은 제품과 서비스를 기준으로 시스템, 키트, 서비스로 구분됩니다.

애플리케이션

  • 진단
  • 약물 발견 및 개발
  • 개인맞춤의학
  • 농업 및 동물 연구
  • 기타

유럽 ​​전체 엑솜 시퀀싱 시장은 응용 분야를 기준으로 약물 발견 및 개발, 농업 및 동물 연구, 진단, 개인화 의학 및 기타로 구분됩니다.

최종 사용자

  • 병원 및 진료소
  • 제약 및 생명공학 회사
  • 학술 및 연구 기관
  • 임상실험실
  • 기타

최종 사용자를 기준으로 볼 때, 유럽 전체 엑솜 시퀀싱 시장은 제약 및 생명 공학 회사, 학술 및 연구 기관, 병원 및 진료소, 임상 실험실 및 기타로 세분화됩니다.

유통 채널

  • 직접 거래
  • 소매 판매
  • 기타

전체 엑솜 시퀀싱 시장

유럽 ​​전체 엑솜 시퀀싱 시장은 유통 채널을 기준으로 직접 거래, 소매 판매 및 기타로 구분됩니다.

전체 엑솜 시퀀싱 시장 국가 수준 분석

엑솜 시퀀싱 시장 전체를 분석하고, 구성 요소, 제품 및 서비스, 응용 프로그램, 최종 사용자 및 유통 채널별로 시장 규모 정보를 제공합니다.

전체 엑솜 시퀀싱 시장 보고서에서 다루는 국가는 독일, 프랑스, ​​이탈리아, 영국, 스페인, 네덜란드, 러시아, 스위스, 터키, 벨기에 및 기타 유럽 국가입니다.

독일은 시퀀싱 비용의 급격한 감소, 주요 기업 및 연구 기관 간의 전략적 제휴로 인해 성장할 것으로 예상됩니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 유럽 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

전체 엑솜 시퀀싱 시장은 또한 모든 국가의 의료 산업 성장에 대한 자세한 시장 분석을 제공합니다. 게다가, 의료 서비스와 치료, 규제 시나리오의 영향, 전체 엑솜 시퀀싱 시장에 대한 추세 매개변수에 대한 자세한 정보를 제공합니다.

경쟁 환경 및 전체 엑솜 시퀀싱 시장 점유율 분석

전체 엑솜 시퀀싱 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 프로그램 우세, 기술 수명선 곡선이 있습니다. 제공된 위의 데이터 포인트는 전체 엑솜 시퀀싱 시장과 관련된 회사의 초점에만 관련이 있습니다.

엑솜 시퀀싱 시장 전체를 다루는 주요 기업으로는 Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx(Bio-Techne의 일부), FOUNDATION MEDICINE, INC.(F. Hoffmann-La Roche Ltd의 자회사), GeneFirst Limited, CeGaT GmbH, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta US Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics(PerkinElmer Inc.의 자회사), GeneDx, LLC, Psomagen, Integrated DNA Technologies, Inc. 등이 있습니다.

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 아시아 태평양 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가에게 전화를 요청하십시오.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE WHOLE EXOME SEQUENCING (WES) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 PRODUCT TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 INDUSTRIAL INSIGHTS:

4.4 CONCLUSION

5 EUROPE WHOLE EXOME SEQUENCING MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 GROWING USAGE OF TARGETED SEQUENCING METHODS

6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING

6.1.3 INCREASING DIAGNOSTICS APPLICATIONS OF WHOLE EXOME SEQUENCING

6.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION

6.2 RESTRAINTS

6.2.1 LESS COMPREHENSIVE COVERAGE OF EXONS

6.2.2 CYBER SECURITY CONCERNS IN GENOMICS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER

6.3.2 INCREASING PRODUCT LAUNCHES IN RECENT YEARS

6.4 CHALLENGES

6.4.1 LACK OF SKILLED PROFESSIONALS

6.4.2 ETHICAL AND LEGAL ISSUES RELATED TO WHOLE EXOME SEQUENCING

7 EUROPE WHOLE EXOME SEQUENCING MARKET, BY COMPONENT

7.1 OVERVIEW

7.2 SECOND-GENERATION SEQUENCING

7.2.1 SEQUENCING BY SYNTHESIS (SBS)

7.2.2 SEQUENCING BY HYBRIDIZATION (SBH) AND SEQUENCING BY LIGATION (SBL)

7.3 THIRD-GENERATION SEQUENCING

8 EUROPE WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE

8.1 OVERVIEW

8.2 SYSTEMS

8.2.1 HISEQ SERIES

8.2.1.1 HISEQ 2500

8.2.1.2 HISEQ 1500

8.2.2 MISEQ SERIES

8.2.3 ION TORRENT PLATFORMS

8.2.3.1 ION PROTON

8.2.3.2 ION PGM

8.2.4 OTHERS

8.3 KITS

8.3.1 DNA FRAGMENTATION, END REPAIR, A-TAILING, AND SIZE SELECTION KITS

8.3.2 LIBRARY PREPARATION KITS

8.3.3 TARGET ENRICHMENT KITS

8.3.4 OTHERS

8.4 SERVICES

8.4.1 SEQUENCING SERVICES

8.4.2 DATA ANALYSIS (BIOINFORMATICS) SERVICES

8.4.3 OTHERS

9 EUROPE WHOLE EXOME SEQUENCING MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 DRUG DISCOVERY AND DEVELOPMENT

9.3 AGRICULTURE & ANIMAL RESEARCH

9.4 DIAGNOSTICS

9.5 PERSONALIZED MEDICINE

9.6 OTHERS

10 EUROPE WHOLE EXOME SEQUENCING MARKET, BY END USER

10.1 OVERVIEW

10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

10.3 ACADEMIC & RESEARCH INSTITUTES

10.4 HOSPITALS AND CLINICS

10.5 CLINICAL LABORATORIES

10.6 OTHERS

11 EUROPE WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TRADE

11.3 RETAIL SALES

11.4 OTHERS

12 EUROPE WHOLE EXOME SEQUENCING MARKET, BY REGION

12.1 EUROPE

12.1.1 GERMANY

12.1.2 FRANCE

12.1.3 U.K.

12.1.4 RUSSIA

12.1.5 ITALY

12.1.6 SPAIN

12.1.7 TURKEY

12.1.8 NETHERLANDS

12.1.9 SWITZERLAND

12.1.10 BELGIUM

12.1.11 REST OF EUROPE

13 EUROPE WHOLE EXOME SEQUENCING MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: EUROPE

14 COMPANY PROFILE

14.1 PERKINELMER GENOMICS (A SUBSIDIARY OF PERKINELMER INC.)

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COM PANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.2 MERCK KGAA

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COM PANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 EXODX (A PART OF BIO-TECHNE)

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COM PANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENTS

14.4 THERMO FISHER SCIENTIFIC INC.

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COM PANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENTS

14.5 FOUNDATION MEDICINE, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COM PANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENTS

14.6 AZENTA US, INC.

14.6.1 COMPANY SNAPSHOT

14.6.2 PRODUCT PORTFOLIO

14.6.3 RECENT DEVELOPMENTS

14.7 BECKMAN COULTER, INC

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENTS

14.8 BIONEER CORPORATION

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT DEVELOPMENTS

14.9 CD GENOMICS

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENTS

14.1 CEGAT GMBH

14.10.1 COMPANY SNAPSHOT

14.10.2 PRODUCT PORTFOLIO

14.10.3 RECENT DEVELOPMENTS

14.11 EUROFINS SCIENTIFIC

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE ANALYSIS

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENTS

14.12 GENEDX, LLC

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 GENEFIRST LIMITED.

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENTS

14.14 ILLUMINA, INC

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENTS

14.15 INTEGRATED DNA TECHNOLOGIES, INC.

14.15.1 COMPANY SNAPSHOT

14.15.2 PRODUCT PORTFOLIO

14.15.3 RECENT DEVELOPMENTS

14.16 MERIDIAN BIOSCIENCE, INC.

14.16.1 COMPANY SNAPSHOT

14.16.2 REVENUE ANALYSIS

14.16.3 PRODUCT PORTFOLIO

14.16.4 RECENT DEVELOPMENTS

14.17 PSOMAGEN

14.17.1 COMPANY SNAPSHOT

14.17.2 REVENUE ANALYSIS

14.17.3 PRODUCT PORTFOLIO

14.17.4 RECENT DEVELOPMENTS

14.18 QIAGEN

14.18.1 COMPANY SNAPSHOT

14.18.2 REVENUE ANALYSIS

14.18.3 PRODUCT PORTFOLIO

14.18.4 RECENT DEVELOPMENTS

14.19 SOPHIA GENETICS

14.19.1 COMPANY SNAPSHOT

14.19.2 REVENUE ANALYSIS

14.19.3 PRODUCT PORTFOLIO

14.19.4 RECENT DEVELOPMENTS

14.2 TWIST BIOSCIENCE

14.20.1 COMPANY SNAPSHOT

14.20.2 REVENUE ANALYSIS

14.20.3 PRODUCT PORTFOLIO

14.20.4 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS

표 목록

TABLE 1 EUROPE WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 2 EUROPE SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 EUROPE SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 4 EUROPE THIRD-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 EUROPE WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 6 EUROPE SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 EUROPE SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 8 EUROPE HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 9 EUROPE ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 10 EUROPE KITS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 EUROPE KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 12 EUROPE SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 EUROPE SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 14 EUROPE WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 15 EUROPE DRUG DISCOVERY AND DEVELOPMENT IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 EUROPE AGRICULTURE & ANIMAL RESEARCH IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 EUROPE DIAGNOSTICS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 EUROPE PERSONALIZED MEDICINE IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 EUROPE OTHERS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 EUROPE WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 21 EUROPE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 EUROPE ACADEMIC & RESEARCH INSTITUTES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 EUROPE HOSPITALS AND CLINICS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 EUROPE CLINICAL LABORATORIES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 EUROPE OTHERS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 EUROPE WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 27 EUROPE DIRECT TRADE IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 EUROPE RETAIL SALES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 EUROPE OTHERS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 EUROPE WHOLE EXOME SEQUENCING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 31 EUROPE WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 32 EUROPE SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 33 EUROPE WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 34 EUROPE SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 35 EUROPE HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 36 EUROPE ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 37 EUROPE KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 38 EUROPE SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 39 EUROPE WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 40 EUROPE WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 41 EUROPE WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 GERMANY WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 43 GERMANY SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 44 GERMANY WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 45 GERMANY SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 46 GERMANY HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 47 GERMANY ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 48 GERMANY KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 49 GERMANY SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 50 GERMANY WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 51 GERMANY WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 GERMANY WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 53 FRANCE WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 54 FRANCE SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 55 FRANCE WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 56 FRANCE SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 57 FRANCE HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 58 FRANCE ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 59 FRANCE KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 60 FRANCE SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 61 FRANCE WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 62 FRANCE WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 63 FRANCE WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 64 U.K. WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 65 U.K. SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 66 U.K. WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 67 U.K. SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 68 U.K. HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 69 U.K. ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 70 U.K. KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 71 U.K. SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 72 U.K. WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 73 U.K. WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 74 U.K. WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 75 RUSSIA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 76 RUSSIA SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 77 RUSSIA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 78 RUSSIA SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 79 RUSSIA HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 80 RUSSIA ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 81 RUSSIA KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 82 RUSSIA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 83 RUSSIA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 84 RUSSIA WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 85 RUSSIA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 86 ITALY WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 87 ITALY SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 88 ITALY WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 89 ITALY SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 90 ITALY HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 91 ITALY ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 92 ITALY KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 93 ITALY SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 94 ITALY WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 95 ITALY WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 96 ITALY WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 97 SPAIN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 98 SPAIN SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 99 SPAIN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 100 SPAIN SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 101 SPAIN HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 102 SPAIN ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 103 SPAIN KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 104 SPAIN SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 105 SPAIN WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 106 SPAIN WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 107 SPAIN WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 108 TURKEY WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 109 TURKEY SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 110 TURKEY WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 111 TURKEY SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 112 TURKEY HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 113 TURKEY ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 114 TURKEY KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 115 TURKEY SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 116 TURKEY WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 117 TURKEY WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 118 TURKEY WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 119 NETHERLANDS WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 120 NETHERLANDS SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 121 NETHERLANDS WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 122 NETHERLANDS SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 123 NETHERLANDS HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 124 NETHERLANDS ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 125 NETHERLANDS KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 126 NETHERLANDS SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 127 NETHERLANDS WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 128 NETHERLANDS WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 129 NETHERLANDS WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 130 SWITZERLAND WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 131 SWITZERLAND SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 132 SWITZERLAND WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 133 SWITZERLAND SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 134 SWITZERLAND HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 135 SWITZERLAND ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 136 SWITZERLAND KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 137 SWITZERLAND SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 138 SWITZERLAND WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 139 SWITZERLAND WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 140 SWITZERLAND WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 141 BELGIUM WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 142 BELGIUM SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 143 BELGIUM WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 144 BELGIUM SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 145 BELGIUM HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 146 BELGIUM ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 147 BELGIUM KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 148 BELGIUM SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 149 BELGIUM WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 150 BELGIUM WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 151 BELGIUM WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 152 REST OF EUROPE WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

그림 목록

FIGURE 1 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: SEGMENTATION

FIGURE 2 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: DROC ANALYSIS

FIGURE 4 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE EUROPE WHOLE EXOME SEQUENCING (WES) MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INCREASE IN USE OF WES TECHNOLOGY FOR NEW SCIENTIFIC APPLICATIONS AND INCREASING THE PREFERENCE OF WES OVER WHOLE-GENOME SEQUENCING IS ITS LOW-COST SEQUENCING CAPABILITY IS EXPECTED TO DRIVE THE EUROPE WHOLE EXOME SEQUENCING (WES) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 13 THE INSTRUMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE WHOLE EXOME SEQUENCING (WES) MARKET IN 2022 & 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE EUROPE WHOLE EXOME SEQUENCING MARKET

FIGURE 15 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, 2021

FIGURE 16 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, 2022-2029 (USD MILLION)

FIGURE 17 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, CAGR (2022-2029)

FIGURE 18 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, LIFELINE CURVE

FIGURE 19 EUROPE WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, 2021

FIGURE 20 EUROPE WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, 2022-2029 (USD MILLION)

FIGURE 21 EUROPE WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, CAGR (2022-2029)

FIGURE 22 EUROPE WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, LIFELINE CURVE

FIGURE 23 EUROPE WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, 2021

FIGURE 24 LOBAL WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, 2022-2029 (USD MILLION)

FIGURE 25 EUROPE WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 26 EUROPE WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 27 EUROPE WHOLE EXOME SEQUENCING MARKET: BY END USER, 2021

FIGURE 28 EUROPE WHOLE EXOME SEQUENCING MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 29 EUROPE WHOLE EXOME SEQUENCING MARKET: BY END USER, CAGR (2022-2029)

FIGURE 30 EUROPE WHOLE EXOME SEQUENCING MARKET: BY END USER, LIFELINE CURVE

FIGURE 31 EUROPE WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 32 EUROPE WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 33 EUROPE WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 34 EUROPE WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 35 EUROPE WHOLE EXOME SEQUENCING MARKET: SNAPSHOT (2021)

FIGURE 36 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021)

FIGURE 37 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2022 & 2029)

FIGURE 38 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021 & 2029)

FIGURE 39 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COMPONENT (2022-2029)

FIGURE 40 EUROPE WHOLE EXOME SEQUENCING MARKET: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The growth rate of the Europe whole exome sequencing market is 16.0% in the forecast period by 2029.
Component, product and service, application, end-user, and distribution channel are the factors on which the Europe whole exome sequencing market research is based.
Major companies in the Europe Whole Exome Sequencing Market are Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx (a part of Bio-Techne), FOUNDATION MEDICINE, INC., GeneFirst Limited, etc.
An increase in the adoption of next-generation sequencing (NGS) & growing usage of targeted sequencing methods are the growth drivers of the Europe whole exome sequencing market.
Germany dominates the Europe whole exome sequencing market due to rapidly declining costs of sequencing, and strategic alliances among major companies and research institutes.